Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
USERS' SCORE
Moderately Good
Based on 17 Reviews
7.8
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin C (as Ascorbyl palmitate)
10 mg
11%
Vitamin K activity
2600 mcg
2167%
Vitamin K1 (as phytonadione)
1500 mcg
Vitamin K2 (as menaquinone-4)
1000 mcg
Vitamin K2 (as trans menaquinone-7)
100 mcg
Top Medical Research Studies
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
7
VKA treatment outcomes in atrial fibrillation
Our study involved a group of 1,350 patients with valvular and nonvalvular atrial fibrillation, all receiving vitamin K antagonists (VKAs). Over about 17 months, we noted an annual incidence of 4.4% for serious events like cardiovascular death and thromboembolic occurrences.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Most Useful Reviews
9
Restores blood clotting
3 people found this helpful
Hello everyone, I dealt with issues related to blood clotting; a simple scratch could take ages to heal. I had my blood sugar checked and found the clotting levels terribly low. After starting these vitamins, the difference was remarkable right away – the effects were noticeable in just a few days. After three weeks, a second test showed my clotting had returned to normal. I’m so pleased and would recommend this product without hesitation!
9
Resolved protein deficiency
Excellent! Great vitamin complex! Thanks to its composition, I am solving two of my issues at once. One relates to deficiencies in certain proteins crucial for blood clotting. I am satisfied with the result.
9
Recommended for absorption
The drug contains vitamins K1 and K2; K1 regulates blood clotting, and K2 aids calcium absorption. An excellent tool that I highly recommend!
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
- All Researches
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
We aimed to find the best antithrombotic regimen for patients with atrial fibrillation (AF) who recently experienced acute coronary syndrome (ACS) or had a percutaneous coronary intervention (PCI).
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
User Reviews
USERS' SCORE
Moderately Good
Based on 17 Reviews
7.8
- All Reviews
- Positive Reviews
- Negative Reviews
9
Restores blood clotting
3 people found this helpful
Hello everyone, I dealt with issues related to blood clotting; a simple scratch could take ages to heal. I had my blood sugar checked and found the clotting levels terribly low. After starting these vitamins, the difference was remarkable right away – the effects were noticeable in just a few days. After three weeks, a second test showed my clotting had returned to normal. I’m so pleased and would recommend this product without hesitation!
9
Resolved protein deficiency
Excellent! Great vitamin complex! Thanks to its composition, I am solving two of my issues at once. One relates to deficiencies in certain proteins crucial for blood clotting. I am satisfied with the result.
9
Recommended for absorption
The drug contains vitamins K1 and K2; K1 regulates blood clotting, and K2 aids calcium absorption. An excellent tool that I highly recommend!
9
Essential for hemostasis
Vitamin K acts as a coenzyme for vitamin K-dependent carboxylase, important for synthesising proteins essential in hemostasis (blood clotting) and bone metabolism. Prothrombin is a vitamin K-dependent protein directly involved in blood clotting. It plays a vital role in forming liver proteins and aids bone restoration by activating calcium binding to bone tissue. The quality of this brand is commendable, and the capsules are of a suitable size with no discernible taste.
7.5
Supports bone health
Super K (Vitamin K) has proven to be a fantastic supplement for supporting bone health and normal blood clotting. After only a few weeks of use, I noticed that my body managed minor cuts and bruises better – they healed faster. Vitamin K helps maintain bone density, especially when paired with calcium and vitamin D. The capsules are small and easy to swallow, offering convenience for those looking to enhance bone health and improve blood clotting, particularly if prone to vitamin K deficiency.
Frequently Asked Questions
9
Restores blood clotting
3 people found this helpful
Hello everyone, I dealt with issues related to blood clotting; a simple scratch could take ages to heal. I had my blood sugar checked and found the clotting levels terribly low. After starting these vitamins, the difference was remarkable right away – the effects were noticeable in just a few days. After three weeks, a second test showed my clotting had returned to normal. I’m so pleased and would recommend this product without hesitation!
7.5
Supports bone health
Super K (Vitamin K) has proven to be a fantastic supplement for supporting bone health and normal blood clotting. After only a few weeks of use, I noticed that my body managed minor cuts and bruises better – they healed faster. Vitamin K helps maintain bone density, especially when paired with calcium and vitamin D. The capsules are small and easy to swallow, offering convenience for those looking to enhance bone health and improve blood clotting, particularly if prone to vitamin K deficiency.
7.5
Supports cardiovascular health
I am thrilled to share my experience with Life Extension Super K Softgels. This supplement has enhanced my cardiovascular and bone health significantly. The blend of vitamins K1 and K2, along with vitamins D and minerals, promotes healthy blood clotting and improves bone density. These softgels are easy to swallow and have become an integral part of my routine. I highly recommend them for anyone looking to improve their overall well-being!
9
Resolved protein deficiency
Excellent! Great vitamin complex! Thanks to its composition, I am solving two of my issues at once. One relates to deficiencies in certain proteins crucial for blood clotting. I am satisfied with the result.
7.5
Enhanced blood clotting
Great product. It improves blood clotting. Before purchasing, I recommend consulting with a doctor!
9
Recommended for absorption
The drug contains vitamins K1 and K2; K1 regulates blood clotting, and K2 aids calcium absorption. An excellent tool that I highly recommend!
6
Increases bone density
Great! I recommend this as an additional source. It enhances bone mineral density. A deficiency in vitamin K2 can lead to osteoporosis, causing bones to weaken and become brittle. Vitamin K2 protects blood vessels from excessive calcification, preventing them from easily becoming clogged with plaques and blood clots.
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
7
Vitamin K's role in clot management
We examined the effectiveness of vitamin K antagonists (VKAs) in patients with antiphospholipid syndrome (APS), a condition that increases the risk of blood clots. Our focus was on how monitoring INR levels affects treatment outcomes.
In a case study with two women suffering from APS, we noted that point-of-care testing often showed misleadingly high INR results. This could lead to inappropriate dosing of VKAs and a higher chance of recurrent clots.
However, our findings suggest that by developing individualized correction factors, we could enhance the accuracy of these tests, helping improve VKA management and patient safety.
In a case study with two women suffering from APS, we noted that point-of-care testing often showed misleadingly high INR results. This could lead to inappropriate dosing of VKAs and a higher chance of recurrent clots.
However, our findings suggest that by developing individualized correction factors, we could enhance the accuracy of these tests, helping improve VKA management and patient safety.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. doi:10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. doi:10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. doi:10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. doi:10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. doi:10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. doi:10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. doi:10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. doi:10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. doi:10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. doi:10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. doi:10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. doi:10.1111/apt.18474
